QID 357231

Date Published: 2024-02-20

QID 357231: Amazon Linux Security Advisory for ipa : ALAS2-2024-2457

A cross-site request forgery vulnerability exists in ipa/session/login_password in all supported versions of ipa.
This flaw allows an attacker to trick the user into submitting a request that could perform actions as the user, resulting in a loss of confidentiality and system integrity.
During community penetration testing it was found that for certain http end-points freeipa does not ensure csrf protection.
Due to implementation details one cannot use this flaw for reflection of a cookie representing already logged-in user.
An attacker would always have to go through a new authentication attempt. (
( CVE-2023-5455)

Note: The preceding description block is extracted directly from the security advisory. Using automation, we have attempted to clean and format it as much as possible without introducing additional issues.

Successful exploitation of this vulnerability could lead to a securitybreach or could affect integrity, availability, and confidentiality.

CVSS V3 rated as High - 6.5 severity.

CVSS V2 rated as Medium - 5.4 severity.

Solution

Please refer to Amazon advisory: ALAS2-2024-2457 for affected packages and patching details, or update with your package manager.

Vendor References

ALAS2-2024-2457 - alas.aws.amazon.com/AL2/ALAS-2024-2457.html

CVEs related to QID 357231

CVE-2023-5455 |

Software Advisories

Advisory ID	Software	Component	Link
ALAS2-2024-2457	amazon linux 2		alas.aws.amazon.com/AL2/ALAS-2024-2457.html

By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].